TECHNOLOGY SPONSOR: Plasma Proteins
Evolve Biologics, one of That's Nice's Road to 2021 sponsors, discusses how the company is envisioning the future of the pharma/biopharma industry.
Originally founded and based in Canada, Evolve is a new kind of biologics company built around a patented next-generation technology that brings critical plasma-derived therapeutics to patients in need.
There are many patients with rare diseases around the world who rely on therapeutics made from the many valuable proteins extracted from human blood plasma. Unfortunately, for more than 75 years, these proteins have been captured through a largely unchanged, yet expensive manufacturing process.
Breakthrough Technology
We believe our patented next-generation technology PlasmaCap EBA® is the first major advancement in the field since the 1940s, allowing us to deliver these critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods. Ultimately, Evolve’s vision is focused on improving patient lives while building a broad and innovative product portfolio in the process. This portfolio would include both existing plasma-derived therapeutics and other proteins not currently commercially available. This would be particularly important where such therapeutic options are currently limited or non-existent, which could include hyperimmune globulins, some of which are currently in development for the potential treatment of COVID-19.
Looking forward to 2021 and beyond, the demand for many of these important plasma-derived therapeutics will continue unabated, especially immunoglobulins based on both existing and future therapeutic indications. We believe that our innovative manufacturing technique will allow us to further advance the quality and availability of plasma-derived therapeutics and to more efficiently extract a broader range of proteins at higher yields, as compared with traditional manufacturing techniques. This efficiency drives reliability and consistency of supply, which is important considering the frequency of product shortages, especially for immunoglobulins.
We believe that our innovative manufacturing technique will allow us to further advance the quality and availability of plasma-derived therapeutics and to more efficiently extract a broader range of proteins at higher yields, as compared with traditional manufacturing techniques.
Phase III Clinical Trials and Beyond
Evolve is currently in the process of completing its phase III clinical trial for intravenous immunoglobulin (IVIG) in both the United States and Canada, as well as building a new fully dedicated commercial facility in North America. The facility will allow the manufacture of plasma-derived therapeutics, initially for the U.S. market. Going forward, we see our scalable and cost-efficient technology becoming available in smaller countries, allowing plasma collected locally to be used to manufacture plasma-derived therapeutics for their own population. The time has come to advance the way plasma-derived therapeutics are delivered, and Evolve is doing just that!
